常用5%白蛋白制品中的氯离子及其他电解质浓度
本研究对加拿大血液服务机构提供的三种5%白蛋白制品(Plasbumin、Alburex、Octalbin)共65份样本进行盲法生化分析,使用Abbott ARCHITECT c8000化学分析仪测定电解质浓度。结果显示三种制品的氯离子和钠离子浓度在所有两两比较及多重比较中均存在显著差异(p < 0.0001)。Plasbumin、Alburex和Octalbin的氯离子平均浓度分别为109.4、123.6和136.8 mmol/L,钠离子平均浓度分别为139.6、137.3和149.4 mmol/L。这是首项记录常用5%白蛋白制品氯离子浓度存在统计学显著差异的研究,该结果已用于设计一项比较高氯与低氯液体用于脓毒症危重患者的初步随机对照试验。
要点
- Plasbumin、Alburex、Octalbin的氯离子平均浓度分别为109.4 mmol/L(SD 1.3)、123.6 mmol/L(SD 1.3)、136.8 mmol/L(SD 0.4),两两比较及多重比较均p < 0.0001。
- 三种制品的钠离子平均浓度分别为Plasbumin 139.6 mmol/L(SD 1.6)、Alburex 137.3 mmol/L(SD 2.2)、Octalbin 149.4 mmol/L(SD 0.5),差异显著(p < 0.0001)。
- 脓毒症复苏中使用高氯液体可能与死亡率增加和肾脏替代治疗使用增加相关,5%人白蛋白是ICU中仅次于晶体的第二常用复苏液体。
- 临床选择5%白蛋白制品时,其氯离子浓度差异显著但常被忽视,Octalbin氯离子浓度最高,Plasbumin最低。
- 该研究结果已用于设计一项初步随机对照试验,探讨高氯与低氯液体对脓毒症危重患者的影响。
适用人群与场景
- ICU中需要液体复苏的脓毒症患者(背景:脓毒症复苏使用高氯液体可能与死亡率增加和肾脏替代治疗使用增加相关;5%人白蛋白是ICU中仅次于晶体的第二常用复苏液体)
研究设计与关键结果
- 研究类型:对三种5%白蛋白制品进行盲法生化分析;样本量:65份白蛋白样本(Plasbumin n=21、Alburex n=24、Octalbin n=20);来源:加拿大血液服务机构;分析地点:加拿大安大略省汉密尔顿市麦克马斯特大学附属学术医院核心实验室。
- 氯离子平均浓度:Plasbumin 109.4 mmol/L(SD 1.3) vs Alburex 123.6 mmol/L(SD 1.3) vs Octalbin 136.8 mmol/L(SD 0.4),所有两两比较及多重比较均p < 0.0001。
- 钠离子平均浓度:Plasbumin 139.6 mmol/L(SD 1.6) vs Alburex 137.3 mmol/L(SD 2.2) vs Octalbin 149.4 mmol/L(SD 0.5),所有两两比较及多重比较均p < 0.0001。
- 采用双尾独立t检验进行所有可能的比较分析,方差分析用于三组比较,显著性阈值设为p小于0.05。
证据类型、等级与局限
- 证据类型:体外盲法生化分析(实验室研究);证据等级:原文未给出。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,临床选择5%白蛋白制品时需注意其氯离子浓度存在统计学显著差异,该差异此前未被记录。
- 该研究结果已用于设计一项初步随机对照试验,探讨高氯与低氯液体对脓毒症危重患者的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Use of hyperchloremic IV fluids for resuscitation in sepsis may be associated with increased mortality and use of renal replacement therapy. After crystalloids, 5% human albumin represents the second most common resuscitation fluid in the ICU. Its chloride concentration is rarely considered in the clinical setting. This study quantifies previously undocumented chloride concentrations of three 5% albumin solutions using biochemical analysis.
DESIGN: We performed blinded analysis of the electrolyte concentration of albumin samples obtained directly from the national blood supplier (Canadian Blood Services). Two-tailed independent t tests were performed for all possible comparative analyses. Analysis of variance testing was performed for relevant three-way comparisons. Significance threshold was set at p less than 0.05.
SETTING: All samples were analyzed in the core laboratory at an academic hospital associated with McMaster University in Hamilton, Ontario, Canada.
SUBJECTS: We analyzed 65 albumin samples from three available brands obtained through Canadian Blood Services. They include Plasbumin (n = 21), Alburex (n = 24), Octalbin (n = 20).
INTERVENTION: Laboratory technologists blinded to product identification measured the concentration of electrolytes, extended electrolytes, lactate, and albumin of each sample using the Abbott ARCHITECT c8000 chemistry analyzer.
MEASUREMENTS AND MAIN RESULTS: The mean chloride concentration of Plasbumin, Alburex, and Octalbin, respectively, were 109.4 mmol/L (SD, 1.3), 123.6 mmol/L (SD, 1.3), and 136.8 mmol/L (SD, 0.4). The mean sodium concentration of Plasbumin, Alburex, and Octalbin, respectively, were 139.6 mmol/L (SD, 1.6), 137.3 mmol/L (SD, 2.2), and 149.4 mmol/L (SD, 0.5). The chloride and sodium concentration differed significantly for all two-way comparisons (p < 0.0001) and multiple comparison testing (p < 0.0001).
CONCLUSION: This study is the first to identify and document a statistically significant variability in the chloride concentration of available 5% albumin products. This study has also informed a pilot randomized controlled trial examining the effect of administering high chloride versus low chloride fluids in critically ill patients with sepsis.
参考来源
- Lai AT, Zeller MP, Millen T, et al. Chloride and Other Electrolyte Concentrations in Commonly Available 5% Albumin Products. Crit Care Med. 2018. PMID: 29293151. doi:10.1097/CCM.0000000000002955
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。